STOCK TITAN

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) announced CEO Matthias Alder's participation in a fireside chat with John Vandermosten, CFA, Senior Analyst for Zacks Small-Cap Research on December 5, 2023.
Positive
  • None.
Negative
  • None.

BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Executive Officer, Matthias Alder, will participate in a fireside chat, hosted by FORCE Family Office, with John Vandermosten, CFA, Senior Analyst for Zacks Small-Cap Research taking place Tuesday, December 5, 2023.

Fireside Chat Details
Date: December 5, 2023
Time: 12:00 p.m. ET
Please register here to attend the live webinar.

An archived replay of the event will be available on the Company’s website here.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287, in development for the treatment of GBA1 Parkinson’s disease, is currently being evaluated in a Phase 1 clinical trial.

Leveraging AI-supported structural biology, proprietary algorithms and supercomputer-powered physics-based models, the company’s SEE-Tx® discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology. For more information, please visit GainTherapeutics.com and follow us on LinkedIn.

Investor & Media Contact:

Susan Sharpe
Linnden Communications
(919) 602-2330
susan@linndencom.com

 


FAQ

When is Gain Therapeutics, Inc. CEO Matthias Alder participating in a fireside chat?

Matthias Alder will participate in a fireside chat on December 5, 2023.

Who is hosting the fireside chat with Gain Therapeutics, Inc. CEO Matthias Alder?

The fireside chat is hosted by FORCE Family Office with John Vandermosten, CFA, Senior Analyst for Zacks Small-Cap Research.

Where can I register to attend the live webinar of the fireside chat?

You can register to attend the live webinar on the Company's website.

Will there be an archived replay of the fireside chat event?

Yes, an archived replay of the event will be available on the Company's website.

Gain Therapeutics, Inc.

NASDAQ:GANX

GANX Rankings

GANX Latest News

GANX Stock Data

48.17M
14.26M
16.45%
10.33%
0.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BETHESDA

About GANX

gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.